Henry Ford Health

Henry Ford Health Scholarly Commons
Cardiology Articles

Cardiology/Cardiovascular Research

4-20-2022

The MANTA vascular closure device: Requiring attention from
beginning to end, reply
Michael Megaly
Ramy Sedhom
Laila Hakam
Santiago Garcia

Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles

CARREV-02677; No of Page 1
Cardiovascular Revascularization Medicine xxx (xxxx) xxx

Contents lists available at ScienceDirect

Cardiovascular Revascularization Medicine

The MANTA vascular closure device: Requiring attention from beginning
to end, reply
Michael Megaly a,⁎, Ramy Sedhom b, Laila Hakam c, Santiago Garcia d
a

Department of Cardiology, Henry Ford Hospital, Detroit, MI, United States of America
Department of Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA, United States of America
Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, United States of America
d
Department of Cardiology, The Christ Hospital, Cinncinati, OH, United States of America
b
c

Editorial Comment
We have read with interest the comment by Chaudhuri and colleagues on our recent paper describing the complications of MANTA closure device (Teleﬂex, PA, USA) reported to the FDA [1]. The authors
make a valid point on the need for more literature on using MANTA
by vascular surgery during endovascular aortic aneurysm repair procedures. However, it should be noted that endovascular procedures represented 20% of patients in the SAFE MANTA study [2]. They also describe
their successful use of the device while being prospectively audited. We
cannot agree more with the points made by the authors on the importance of meticulous techniques for access and closure to avoid the complications of MANTA mentioned in the original manuscript.
As Chaudhuri et al. mentioned, the MANTA device has been mainly
studied in the TAVR population. Another cohort of patients lacking research on the use of MANTA for closure is the cardiogenic shock and mechanical circulatory support (MCS) cohort [2]. These patients represent
the highest risk for vascular closure complications due to their high-risk
proﬁles and the urgency when placing the MCS device. In emergencies,
the premeasurement step is usually ignored, increasing the risk of measuring and deployment errors. These patients also tend to have MCS
devices for a prolonged period, potentially developing groin hematomas
altering the original measured depth if present. In our center, we have
developed a solution to overcome these pitfalls. All our femoral accesses
are performed with ﬂuoroscopy and ultrasound guidance, and the exact
puncture site is always saved on ﬂuoroscopy. We have developed a
method to use a ﬂuoroscopy-guided MANTA deployment technique as
follows: 1) exchange the MCS device for MANTA as regular, 2) start
retracting the device under ﬂuoroscopy until the tip of the device is

1 cm above the access site reviewed on ﬂuoroscopy, 3) release the
anchor and deploy the device as regular. This technique has been very
successful in our experience. Although the 14-Fr. depth locator will
help mitigate the risks of measurement errors with the Impella CP
device (Abiomed, USA), ﬂuoroscopy-guided MANTA closure would
still be needed in larger arterial sheaths (e.g., ECMO and TandemHeart devices (LivaNova, USA)).
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